Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.42 0.04 (0.74%) Market Cap: 775.16 Mil Enterprise Value: 538.07 Mil PE Ratio: 0 PB Ratio: 2.17 GF Score: 73/100

Q3 2021 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Nov 03, 2021 / 12:30PM GMT
Release Date Price: $30.39 (-5.03%)
Operator

Greetings, and welcome to Aurinia Pharmaceuticals' Third Quarter 2021 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host Dana Lynch, Aurinia's Investor Relations and Corporate Communications. Thank you. You may begin.

Dana Lynch;Director
Corporate Communications,

Thank you, Latonya, and thank you to those joining today's call to discuss Aurinia's third quarter financial results. Leading the call this morning are Peter Greenleaf, President and CEO; and Joe Miller, Chief Financial Officer. Other members of the Aurinia executive team, Max Colao, Chief Commercial Officer; Neil Solomons, Chief Medical Officer; and Robert Huizinga, Executive Vice President of Research, are also on the call and available for the Q&A portion of the agenda. Today, Peter will begin with an update on our progress with LUPKYNIS commercialization, review recent and anticipated clinical and regulatory milestones for voclosporin as well as provide an update on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot